2016 Fiscal Year Final Research Report
Treatment of mTOR inhibtor-induced lung disease
Project/Area Number |
15K19426
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Respiratory organ internal medicine
|
Research Institution | Jichi Medical University |
Principal Investigator |
|
Research Collaborator |
Ushijima Kentaro 自治医科大学, 医学部, 講師 (70448843)
|
Project Period (FY) |
2015-04-01 – 2017-03-31
|
Keywords | mTOR阻害薬 / Temsirolimus / 肺傷害 / 糖尿病 / 血糖降下薬 |
Outline of Final Research Achievements |
mTOR inhibitors have recently been developed as antineoplastic targeted therapies in various cancers. However, mTOR inhibitors have several adverse effects, including interstitial lung disease and type 2 diabetes. We recently found that temsirolimus induced interstitial lung disease more frequently in patients with diabetes. It was the purpose of this experiment to reveal the association between temsirolimus-induced lung disease and type 2 diabetes. Male moderate diabetic mice or control mice were administered by temsirolimus or vehicle. A subgroup of diabetic mice administered with temsirolimus was treated by rosilgitazone maleate, glimepiride, or vehicle. Temsirolimus worsened type 2 diabetes markedly in diabetic mice. However, lung inflammation in diabetic mice was equivalent to that in control mice. Rosiglitazone ameliorated temsirolimus-induced type 2 diabetes but not lung inflammation. Glimepiride did not ameliorate temsirolimus-induced type 2 disbetes.
|
Free Research Field |
泌尿器科
|